跳至主要内容
临床试验/EUCTR2008-005909-19-GB
EUCTR2008-005909-19-GB进行中(未招募)1 期

Does extra fine HFA-BDP suppress small airways inflammation in COPD? - PAW002

The University of Dundee0 个研究点目标入组 24 人开始时间: 2009年1月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Male or female >40 years old.
  • 2) Post bronchodilator FEV1/FVC ratio of <0.7 and FEV1<80% predicted
  • 3) Smoking history of =15 pack years
  • 4) Small airways inflammation, characterised by elevated CANO (>3ppb).
  • 5) Ability to comply with the requirements of the protocol.
  • 6) Ability to give informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years)
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) Oral steroid use or exacerbation within 6 weeks. Greater than 2 exacerbations requiring treatment in the previous 6 months.
  • 2) Requirement for domiciliary oxygen.
  • 3) Diagnosis of asthma.
  • 4) Significant concomitant respiratory disease including bronchiectasis, ABPA, cystic fibrosis or cor pulmonale.
  • 5) Any other clinically significant medical condition that may either endanger the health or safety of the participant, or jeopardise the protocol.
  • 6) Any significantly abnormal laboratory result as deemed by the investigators.
  • Use of oral corticosteroids within the last 2 months.
  • 7) Pregnancy, planned pregnancy or lactation.
  • 8) Known or suspected contra-indication to any of the IMPs.
  • 9) Concomitant use of medicines (prescribed, over-the counter or herbal) that may interfere with the trial.

研究者

发起方
The University of Dundee

相似试验